

## Project ECHO for Interstitial Lung Disease

Wednesday, September 21, 2022, 7am-8am

Medical Director	Robert Hallowell, MD
Principal Investigator	Aliaa Barakat, PhD
Didactic Speaker	Barry Shea, MD
Session Facilitator	Peter LaCamera, MD
Target Audience	The series is designed for pulmonologists and radiologists, and for other health providers who care for people with ILD.

**In accordance with HIPAA:** All patient information will be de-identified during session.

Time	Didactic Presentation / Case Discussion	Presenter / Facilitator
7:00am-7:05am	Announcements and Introductions	Aliaa Barakat, PhD Robert Hallowell, MD
7:05am-7:25am	Didactic: Shifting Paradigms of IPF Pathogenesis	Barry Shea, MD
7:25am-8:00am	Case Presentation and Discussion	Peter LaCamera, MD
8am	Closing Remarks	Arthur Dea, CCRP



In support of improving patient care, this activity has been planned and implemented by the Pulmonary Care and Research Collaborative, Ltd. and Project ECHO®. Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



### AMA Designation Statement

Project ECHO® designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only credit commensurate with the extent of their participation in the activity.

### ECHO Activity ID: RSS330

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.

## Disclosure Statement

Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.

None of the following planners / presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Arthur Dea, BA, CCRP; Fiona Gibbons, MD.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

Name	Nature of Relationship	Name of Ineligible Company
Aliaa Barakat, PhD	Principal Investigator of investigator-initiated research	Genentech, Inc.
Katharine Black, MD	Basic Science Researcher	Celgene/Bristol-Myers-Squibb, Bayer AG
Leo Ginns, MD	Site Principal Investigator for multicenter clinical trial	Nitto Denko
Robert Hallowell, MD	Site Principal Investigator or Co-Investigator for multicenter clinical trial	Galapagos NV, Hoffman La-Roche, Nitto Denko
	Former Medical Advisory Board Member	Boehringer Ingelheim
	Editor and/or Content Contributor	Dynamed, UpToDate
Peter LaCamera, MD	Principal Investigator of investigator-initiated research	Boehringer Ingelheim
	Site Principal Investigator for multicenter clinical trial	Galapagos NV, Boehringer Ingelheim, Theravance Biopharma, Bristol-Myers Squibb
Barry Shea, MD	Site Principal Investigator for multicenter clinical trial	Galapagos NV, FibroGen

All of the relevant financial relationships listed for these individuals have been mitigated.

### ECHO Activity ID: RSS330

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.